Worldwide BiTE Antibodies Industry to 2025 - Players Include Amgen, Bayers & Micromet Among Others
February 23, 2021 05:38 ET
|
Research and Markets
Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Global BiTE Antibodies Market , Price, Sales & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. This...
Global Advanced Antibodies Report 2020 with Profiles of Key Companies - Advances in Antibody-based Therapies, Bispecific Antibodies (bsAbs) have Gained Momentum
January 21, 2021 07:03 ET
|
Research and Markets
Dublin, Jan. 21, 2021 (GLOBE NEWSWIRE) -- The "Advanced Antibodies, 2020" report has been added to ResearchAndMarkets.com's offering. This report profiles companies (excluding Tier 1...
Qu Biologics Completes $8M Financing
December 09, 2020 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
September 17, 2020 06:00 ET
|
Provectus Biopharmaceuticals Inc.
62% 2-year OS; median OS not reachedStable, non-overlapping safety profileClinical synergy between PV-10 and immune checkpoint blockadeData compare favorably to approved therapies for patient...
CLS and Advanced Medical Systems Form Joint Venture Cooperation, Introducing the Innovative TRANBERG® Thermal Therapy System and imILT® in the Asia-Pacific Region
August 24, 2020 03:00 ET
|
Clinical Laserthermia Systems Americas, Inc.
LUND, Sweden, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS), developer of innovative image-guided laser ablation technology for minimally invasive soft tissue and...
Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer
August 18, 2020 14:35 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Provectus Announces Presentation of Preliminary Results from Phase 1 Trial of PV-10® (rose bengal disodium) for Treatment of Metastatic Uveal Melanoma at ESMO I-O Congress 2019
December 12, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
13 patients treated to date have received single-agent PV-10 or combination of PV-10 and standard of care checkpoint blockadeIndependent safety profiles of PV-10 and checkpoint inhibition were...
CLS Presents Image-Guided Laser Thermotherapy Enhancements at MedTech Investing Europe Conference in London, UK
November 25, 2019 03:00 ET
|
Clinical Laserthermia Systems Americas, Inc.
LONDON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS) will present its high precision, image-guided TRANBERG® çLaser Thermal Therapy System, new MRI-integrated...
PV-10-based Cancer Combination Therapy Clinical Trial Design Wins Australasian Gastro-Intestinal Trials Group’s New Concepts Award
August 27, 2019 09:00 ET
|
Provectus Biopharmaceuticals Inc.
Two-stage, 34-patient, Phase 2 study combines PV-10 and Keytruda® (pembrolizumab) for treatment of metastatic neuroendocrine tumorsCombination powered for 19% ORR vs 3.7% ORR for Keytruda...
Vaccex, Inc is pleased to announce the formal engagement of Dr. Per Horn as President and Chief Executive Officer
July 09, 2019 09:00 ET
|
Vaccex Inc
BOSTON, July 09, 2019 (GLOBE NEWSWIRE) -- Vaccex, Inc. (OTC: VCEX), a Boston, Massachusetts-based biotechnology company that is developing immunotherapies for the treatment of cancer, announced...